TEST CURRENTLY NOT PERFOMED AT THE RISHL The Abbott Laboratories SARS-CoV-2 IgG serological test is an immunoassay for the qualitative detection of IgG antibodies to SARS-CoV-2 in human serum and plasma using chemiluminescent microparticle immunoassay (CMIA) technology. The Abbott Laboratories SARS-CoV-2 IgG assay is only for use under a Food and Drug Administration Emergency Use Authorization. The performance characteristics of this assay were validated by the Rhode Island State Health Laboratories (RISHL). Results should be used in conjunction with the patient's clinical symptoms, medical history, and other clinical/laboratory findings to determine an overall clinical diagnosis. Results should not be used to infer an immunity status nor predict resistance or susceptibility to a future exposure to SARS-CoV-2. Provider Fact Sheet: https://www.fda.gov/media/137381/download Patient Fact Sheet: https:www.fda.gov/media/137382/download |